Related Experiment Video
Updated: Sep 21, 2026
Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
Published on: September 3, 2016
[Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer]
Ying-cheng Lin1, Yi Lin, Wen Lin
1Department of Medical Oncology, Cancer Hospital, P. R. China. Lyc-1@21cn.com
Background & Objective:
The platinum-combination chemotherapy has been proved to be benefit to the patients with advanced non-small cell lung cancer (NSCLC), but the suitable regimen of chemotherapy has been much debated during the last decade. This study was designed to compare MIP regimen [mitomycin + ifosfamid + cisplatin], TP regimen [Taxol + cisplatin], and DP regimen [docetaxel + cisplatin] and to evaluate the efficacy of the three regimens in patients with advanced NSCLC.
Methods:
Ninety-two patients were enrolled in this study, 32 for MIP, 30 for TP, and 30 for DP. The characteristics of patients were comparable except there were more stage IV patients and second chemotherapy patients in DP group.
Results:
For MIP, TP, and DP groups, the objective response rates were 43.8%, 40%, and 46.7%, respectively; the median duration of survival were 11, 10, and 12 months respectively; the 1 year survival rate were 46%, 40%, and 50%, respectively. The major toxicities were bone marrow suppression, nausea, vomiting, and alopecia.
Conclusions:
MIP, TP, and DP regimens are effective and safe chemotherapy protocols for the treatment of advanced NSCLC patients.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
